Figure 3.

Osteoglycin treatment controls glucose and insulin homeostasis. (A) Glucose levels during a pilot glucose tolerance test in WT mice treated with either PBS or different doses of osteoglycin 4 h prior to the test. (B) Glucose and (C) insulin levels in fasted WT mice 4 h after treatment with either osteoglycin or PBS. (D) Glucose levels during a glucose tolerance test and (E) expressed as area under the curve in chow-fed WT mice as well as (F) glucose levels during a glucose tolerance test in HFD-fed WT mice treated with either osteoglycin or PBS 4 h prior to the test. (G) Insulin levels during the glucose tolerance test in chow-fed WT mice treated with either osteoglycin or PBS 4 h prior to the test. (H) Glucose levels during an insulin tolerance test in WT mice treated with either osteoglycin or PBS 4 h prior to the test. (I–J) pAkt (Ser473) in quadriceps muscle of WT mice treated with osteoglycin or PBS followed by either saline or insulin (0.5 IU/kg) 4 h later. (I) pAkt to Akt ratios of treatment relative to untreated group; (J) representative immunoblots. Data are means ± SEM of at least 10 mice per group, except >3 mice per group for pilot study (A), and 4–6 mice per group for pAkt experiment (I–J). * = p < 0.05, ** = p < 0.01 as indicated; ˆ = p < 0.05, ˆˆ = p < 0.01 OGN treatment effect over time compared to PBS as measured by repeated measures ANOVA.